GlassScriptPhysician profile
Gregory P Papa
NPI 1730242397
$66,969.40
in general payments reported to CMS, 2019-2025
50 companies · $3,664 in 2025
The $3,664 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,471 · 2020: $19K · 2021: $20K · 2022: $6,552 · 2023: $4,248 · 2024: $4,146 · 2025: $3,664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $12.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,046.02 |
| Education | $12.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $24,729.51 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $10,309.09 | 2020-2021 | |
| Abbvie INC. | $7,811.19 | 2021-2025 | |
| Novo Nordisk INC | $3,759.46 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,909.13 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Biohaven Pharmaceutical Holding Company LTD. | $2,784.86 | 2022 | |
| Glaxosmithkline, LLC. | $1,849.09 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $1,746.92 | 2019-2025 | |
| Axsome Therapeutics, INC. | $1,599.11 | 2023-2025 | Sunosi, Auvelity |
| Janssen Pharmaceuticals, INC | $875.72 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $772.55 | 2019-2025 | Veozah, Myrbetriq |
| Jazz Pharmaceuticals INC. | $755.71 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $616.04 | 2019-2025 | Jardiance |
| Alkermes, INC. | $610.92 | 2019-2025 | Lybalvi, Vivitrol, Vivitrol |
| Kowa Pharmaceuticals America, INC. | $575.90 | 2020-2025 | Livalo, Seglentis, Zoryve |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $542.90 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Corcept Therapeutics | $504.75 | 2024-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $491.60 | 2019-2024 | |
| Daiichi Sankyo INC. | $450.97 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $395.88 | 2022-2025 | Caplyta |
| Abbott Laboratories | $321.84 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $286.17 | 2020-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $242.73 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Amarin Pharma, INC. | $224.45 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $202.22 | 2023-2025 | Ingrezza |
| Braeburn INC. | $178.56 | 2024-2025 | Brixadi |
| Takeda Pharmaceuticals U.S.A., INC. | $165.56 | 2019-2022 | |
| Dexcom, INC. | $138.40 | 2023-2025 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $122.35 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $119.71 | 2019-2024 | |
| Mylan Specialty L.P. | $103.49 | 2021-2023 | Yupelri |
| Amgen INC. | $101.21 | 2022-2025 | Repatha, Otezla, Otezla |
| Indivior INC. | $85.02 | 2024-2025 | Sublocade |
| Corium, LLC | $82.34 | 2022 | |
| Phathom Pharmaceuticals, INC. | $75.63 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $68.16 | 2023 | Cologuard Collection Kit |
| Ardelyx, INC. | $44.24 | 2024-2025 | Ibsrela |
| Medtronic, INC. | $41.36 | 2021-2023 | Synchromedii |
| Vanda Pharmaceuticals INC. | $35.29 | 2024-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $34.74 | 2020 | |
| Ironwood Pharmaceuticals, INC | $33.40 | 2020 | |
| Idorsia Pharmaceuticals US INC | $32.13 | 2023 | Quviviq |
| Tactile Systems Technology INC | $27.19 | 2024 | Entre Plus, Flexitouch Plus |
| Otsuka America Pharmaceutical, INC. | $24.28 | 2023 | Rexulti |
| Almatica Pharma LLC | $16.55 | 2023 | Gralise |
| Evoke Pharma, INC. | $16.19 | 2025 | |
| Insulet Corporation | $15.25 | 2025 | Omnipod |
| Resmed Corp | $15.12 | 2019 | |
| Eisai INC. | $12.65 | 2021 | |
| Shire North American Group INC | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Papa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.